pegasys
pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 en 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. met betrekking tot het besluit tot inleiding van de behandeling bij pediatrische patiënten zie punt 4. 2, 4. 4 en 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 en 5. voor hepatitis-c-virus (hcv) genotype specifieke activiteit, zie de paragrafen 4. 2 en 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. bij de beslissing om te starten van de behandeling in de kindertijd, is het belangrijk rekening te houden met de groeiremming veroorzaakt door een combinatie therapie. de omkeerbaarheid van de groeiremming is onzeker. de beslissing om de behandeling moet worden gemaakt op een geval per geval (zie paragraaf 4.
virbagen omega
virbac s.a. - recombinant omega-interferon van oorsprong van katten - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. bij katten die met fiv waren geïnfecteerd, was de mortaliteit laag (5%) en werd deze niet beïnvloed door de behandeling.
iso-betadine 5 % spoeloploss.
viatris healthcare sa-nv - povidon-jood 5 g/100 ml - spoeloplossing - 5 % - povidon-jood 50 mg/ml - povidone-iodine
iso-betadine gel 10 % zalf
viatris healthcare sa-nv - povidon-jood 10 g/100 g - zalf - 10 % - povidon-jood 100 mg/g - povidone-iodine
iso-betadine buccale 1 % oromucos. opl.
viatris healthcare sa-nv - povidon-jood 1 g/100 ml - oplossing voor oromucosaal gebruik - 1 % - povidon-jood 10 mg/ml - povidone-iodine
iso-betadine dermique 10 % cut. opl. amp.
viatris healthcare sa-nv - povidon-jood 10 g/100 ml - oplossing voor cutaan gebruik - 10 % - povidon-jood 100 mg/ml - povidone-iodine; g01ax11 povidone-iodine; d08ag02 povidone-iodine
iso-betadine gynecologie 10 % vagin. opl.
viatris healthcare sa-nv - povidon-jood 10 g/100 ml - oplossing voor vaginaal gebruik - 10 % - povidon-jood 100 mg/ml - povidone-iodine
iso-betadine pansement humide 10 % geïmpr. verbandgaas sachet
viatris healthcare sa-nv - povidon-jood >= 60 mg/g - geïmpregneerd verbandgaas - 10 % - povidon-jood 100 mg/g - povidone-iodine
iso-betadine savon germicide 7.5 % cut. opl.
viatris healthcare sa-nv - povidon-jood 7,5 g/100 ml - oplossing voor cutaan gebruik - 7,5 % - povidon-jood 75 mg/ml - povidone-iodine
iso-betadine solution hydroalcoolique 5 % cut. opl. amp.
viatris healthcare sa-nv - ethanol 96% 0,72 ml/ml - eq. ethanol 0,692 ml/ml; povidon-jood 50 mg/ml - oplossing voor cutaan gebruik - 5 % - povidon-jood 50 mg/ml; ethanol 96% 0.72 ml/ml - povidone-iodine